A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma

Objective:To review the current management, outline recent advances and address controversies in the management of hepatocellular carcinoma (HCC). Summary of Background data:The treatment of HCC is multidisciplinary involving hepatologists, surgeons, medical oncologists, radiation oncologists, radiologists, interventional radiologists, and other disciplines. Each of these disciplines brings its unique perspective and differing opinions that add to controversies in the management of HCC. Methods:A focused literature review was performed to identify recent studies on the management of HCC and thereby summarize relevant information on the various therapeutic modalities and controversies involved in the treatment of HCC. Results:The main treatment algorithms continue to rely on hepatic resection or transplantation with controversies involving patients harboring early stage disease and borderline hepatic function. The other treatment strategies include locoregional therapies, radiation, and systemic therapy used alone or in combination with other treatment modalities. Recent advances in locoregional therapies, radiation, and systemic therapies have provided better therapeutic options with curative intent potential for some locoregional therapies. Further refinements in combination therapies such as algorithms consisting of locoregional therapies and systemic or radiation therapies are likely to add additional options and improve survival. Conclusions:The management of HCC has witnessed significant strides with advances in existing options and introduction of several new treatment modalities of various combinations. Further refinements in these treatment options combined with enrollment in clinical trials are essential to improve the management and outcomes of patients with HCC.

[1]  R. Kamel AASLD 2016 Recommendations for Testing, Managing, and Treating Hepatitis C , 2017 .

[2]  D. Samuel,et al.  Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. , 2015, Radiology.

[3]  A. Luciani,et al.  Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. , 2015, Journal of hepatology.

[4]  Goran Klintmalm,et al.  Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? , 2015, Journal of the American College of Surgeons.

[5]  Brice Gayet,et al.  Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. , 2015, Annals of surgery.

[6]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[7]  T. Pawlik,et al.  Hepatobiliary cancers, version 2.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  K. Hu Advances in clinical application of cryoablation therapy for hepatocellular carcinoma and metastatic liver tumor. , 2014, Journal of clinical gastroenterology.

[9]  L. Dawson,et al.  Radiation therapy for liver tumors: ready for inclusion in guidelines? , 2014, The oncologist.

[10]  Lequn Li,et al.  Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review , 2014, Tumor Biology.

[11]  H. Schlitt,et al.  Is Resection or Transplantation the ideal Treatment in Patients with Hepatocellular Carcinoma in Cirrhosis if Both Are Possible? A Systematic Review and Metaanalysis , 2014, Annals of Surgical Oncology.

[12]  J. Seong,et al.  Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma , 2014, Journal of Cancer Research and Clinical Oncology.

[13]  F. Gao,et al.  Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis , 2014, Tumor Biology.

[14]  Yi-jun Wang,et al.  Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. , 2013, European journal of radiology.

[15]  Yao-ting Chen,et al.  Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. , 2013, World journal of gastroenterology.

[16]  G. Abou-Alfa,et al.  The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? , 2013, The Lancet. Oncology.

[17]  Y. Kuo,et al.  Laparoscopic versus open liver resection: a meta-analysis of long-term outcome , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[18]  J. Shindoh,et al.  Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. , 2013, Journal of the American College of Surgeons.

[19]  M. Schwartz,et al.  Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[20]  Shu-sen Zheng,et al.  Recipient outcomes of salvage liver transplantation versus primary liver transplantation: A systematic review and meta‐analysis , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  J. Shindoh,et al.  Portal Vein Embolization for Hepatocellular Carcinoma , 2012, Liver Cancer.

[22]  F. Roudot-thoraval,et al.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. , 2012, Gastroenterology.

[23]  Yuman Fong,et al.  Ablation of perivascular hepatic malignant tumors with irreversible electroporation. , 2012, Journal of the American College of Surgeons.

[24]  Lynette M. Smith,et al.  Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[25]  L. Koniaris,et al.  Is Resection Equivalent to Transplantation for Early Cirrhotic Patients with Hepatocellular Carcinoma? A Meta-Analysis , 2012, Journal of Gastrointestinal Surgery.

[26]  O. V. van Delden,et al.  Portal Vein Embolization Before Liver Resection: A Systematic Review , 2012, CardioVascular and Interventional Radiology.

[27]  G. Tsoulfas,et al.  Surgical treatment for large hepatocellular carcinoma: does size matter? , 2012, ANZ journal of surgery.

[28]  G. Torzilli,et al.  A Comprehensive Meta-regression Analysis on Outcome of Anatomic Resection Versus Nonanatomic Resection for Hepatocellular Carcinoma , 2012, Annals of Surgical Oncology.

[29]  J. Bruix,et al.  Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. , 2012, Journal of hepatology.

[30]  J. Seong,et al.  The Optimal Selection of Radiotherapy Treatment for Hepatocellular Carcinoma , 2012, Gut and liver.

[31]  N. Petrucciani,et al.  Hepatocellular Carcinomas and Primary Liver Tumors as Predictive Factors for Postoperative Mortality after Liver Resection: A Meta-Analysis of More than 35,000 Hepatic Resections , 2012, The American surgeon.

[32]  M. Choti,et al.  National trends in surgical procedures for hepatocellular carcinoma: 1998‐2008 , 2012, Cancer.

[33]  M. Sawyer,et al.  Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? , 2012, Cancer treatment reviews.

[34]  J. Bruix,et al.  Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Xiaohua Liu,et al.  Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta‐analysis , 2012, Journal of gastroenterology and hepatology.

[36]  Lynette M. Smith,et al.  External validation of a pre-operative nomogram predicting peri-operative mortality risk after liver resections for malignancy. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[37]  G. Abou-Alfa TACE and sorafenib: a good marriage? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  T. Pawlik,et al.  Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Feng,et al.  Radiation therapy for hepatocellular carcinoma. , 2011, Seminars in radiation oncology.

[40]  M. Mulcahy,et al.  Radioembolization for primary and metastatic liver cancer. , 2011, Seminars in radiation oncology.

[41]  T. Hong,et al.  Charged-particle therapy for hepatocellular carcinoma. , 2011, Seminars in radiation oncology.

[42]  P. Friend,et al.  Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria , 2011, The British journal of surgery.

[43]  Masaya Sato,et al.  Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review , 2011, European Radiology.

[44]  Jürgen Weitz,et al.  Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). , 2011, Surgery.

[45]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[46]  A. Siegel,et al.  Sorafenib: Where do we go from here? , 2010, Hepatology.

[47]  W. Chapman,et al.  Surgical treatment of hepatocellular carcinoma: expert consensus statement. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[48]  G. Abou-Alfa,et al.  Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[49]  T. Vogl,et al.  Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. , 2010, AJR. American journal of roentgenology.

[50]  R. Freeman,et al.  Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[51]  D. Geller,et al.  World Review of Laparoscopic Liver Resection—2,804 Patients , 2009, Annals of surgery.

[52]  M. Choti,et al.  Predictors of Survival After Resection of Early Hepatocellular Carcinoma , 2009, Annals of surgery.

[53]  Angelo Andriulli,et al.  Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials , 2009, The American Journal of Gastroenterology.

[54]  J. Belghiti,et al.  Prospective Validation of the “Fifty-Fifty” Criteria as an Early and Accurate Predictor of Death After Liver Resection in Intensive Care Unit Patients , 2009, Annals of surgery.

[55]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[56]  J. Trotter,et al.  Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[57]  Y. Nishiyama,et al.  Detection of Hepatocellular Carcinoma Using 11C-Choline PET: Comparison with 18F-FDG PET , 2008, Journal of Nuclear Medicine.

[58]  J. Vauthey,et al.  Standardized Liver Volumetry for Portal Vein Embolization , 2008, Seminars in interventional radiology.

[59]  R. Lencioni,et al.  Treatment before Liver Transplantation for HCC , 2008, Annals of Surgical Oncology.

[60]  G. Jung,et al.  Model for end-stage liver disease , 2008, Der Chirurg.

[61]  N. Habib,et al.  Preoperative Portal Vein Embolization for Major Liver Resection: A Meta-Analysis , 2008, Annals of surgery.

[62]  W. Kim,et al.  The model for end‐stage liver disease (MELD) , 2007, Hepatology.

[63]  M. Gonen,et al.  Perihepatic Lymph Node Assessment in Patients Undergoing Partial Hepatectomy for Malignancy , 2006, Annals of surgery.

[64]  Guy Marchal,et al.  Local Recurrence After Hepatic Radiofrequency Coagulation: Multivariate Meta-Analysis and Review of Contributing Factors , 2005, Annals of surgery.

[65]  Fernando Pons,et al.  Staging systems in hepatocellular carcinoma. , 2005, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[66]  Yi-Cheng Chen,et al.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. , 2004, Gastroenterology.

[67]  W. Grigioni,et al.  The Role of Lymphadenectomy for Liver Tumors: Further Considerations on the Appropriateness of Treatment Strategy , 2004, Annals of surgery.

[68]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[69]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[70]  L. Y. Wang,et al.  Clinical utility of pulsed Doppler in the detection of arterioportal shunting in patients with hepatocellular carcinoma , 1992, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[71]  Tyler J. Fraum,et al.  Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. , 2018, Radiology.

[72]  A. Darzi,et al.  A Systematic Review of the Impact of Dedicated Emergency Surgical Services on Patient Outcomes. , 2016, Annals of surgery.

[73]  A. Thakor,et al.  Y90 selective internal radiation therapy. , 2015, Surgical oncology clinics of North America.

[74]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[75]  W. Chapman,et al.  Transplantation for hepatocellular carcinoma: the North American experience. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[76]  R. Lencioni,et al.  Local-regional treatment of hepatocellular carcinoma. , 2012, Radiology.

[77]  P. Bossuyt,et al.  Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. , 2012, The Lancet. Oncology.

[78]  V. Mazzaferro,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, European journal of cancer.

[79]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[80]  G. Paumgartner,et al.  European Association for the Study of the Liver , 2006 .

[81]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.